Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
Vismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for monotherapy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined modality treatment by vismodegib and radiation therapy, however, are rare. In the present study, we examined the radiation se...
Main Authors: | Stephanie Hehlgans, Patrick Booms, Ömer Güllülü, Robert Sader, Claus Rödel, Panagiotis Balermpas, Franz Rödel, Shahram Ghanaati |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/19/9/2485 |
Similar Items
-
Vismodegib: The first drug approved for advanced and metastatic basal cell carcinoma
by: A K Dubey, et al.
Published: (2013-01-01) -
Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
by: Suruchi Aditya, et al.
Published: (2013-01-01) -
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
by: Glen J. Weiss, et al.
Published: (2011-12-01) -
Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
by: Maxwell G. Su, et al.
Published: (2020-09-01) -
Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma
by: Jaeyoung Yoon, MD, PhD
Published: (2021-01-01)